Q1 FY27 results: revenue up 17% YoY, profit drops 45%

Ebitda Margin CompressionResults View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹960.00

prior close

₹929.70

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+1.5% vs market

Pharmaceuticals peers, median of 164sector+0.1%+1.7% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

+0.1

15m

+1.4

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+0.2+1.5+0.1+1.7

Next day

-8.1-0.1-8.0-0.4-7.7

-7.4+0.1-7.5+0.1-7.5

-10.2-0.4-9.8-0.4-9.8

-9.9-0.2-9.7-0.9-9.0

-10.0+0.0-10.0-0.5-9.5

-9.9-0.0-9.9-1.0-8.9

15d

-6.0+0.1-6.1-0.6-5.5

+6.8-0.0+6.8+0.9+5.8

+0.5-3.1+3.6-3.1+3.6

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova posted Q1 FY27 consolidated revenue of Rs 2,229 crore, up 17.3% YoY but down 2.6% QoQ. Net profit fell 45% YoY to Rs 56 crore from Rs 103 crore. EBITDA margin contracted to about 12% from 15.9% YoY. CDMO Sterile Injectables grew 32% and Radiopharma 18%, while Generics swung to a loss of Rs 10 crore. Auditor Walker Chandiok gave a clean review report with no qualifications.

Likely market impact

Sharp profit fall and margin compression may weigh on the stock, though strong Radiopharma and CDMO growth signal underlying business momentum.